Table 2.
Summary of ROC analysis
| AUC (95% CI) | Threshold | Specificity | Sensitivity | p-valuea (vs CA19-9) | |
|---|---|---|---|---|---|
| All stage | |||||
| CA19-9 | 0.842 (0.755–0.930) | 11.7 | 0.769 | 0.846 | |
| CD63+-EVs | 0.846 (0.752–0.941) | 0.016 | 0.846 | 0.821 | 0.945 |
| CD41+-EVs | 0.678 (0.552–0.804) | 0.079 | 0.744 | 0.718 | 0.0290 |
| CD61+-EVs | 0.652 (0.527–0.776) | 0.045 | 0.641 | 0.718 | 0.00932 |
| CD63+-EVs × CA19-9 | 0.903 (0.823–0.984) | 0.136 | 0.872 | 0.897 | 0.124 |
| Early stage (I–II) | |||||
| CA19-9 | 0.814 (0.699–0.929) | 11.7 | 0.769 | 0.87 | |
| CD63+-EVs | 0.858 (0.745–0.971) | 0.011 | 0.0769 | 0.913 | 0.557 |
| CD41+-EVs | 0.685 (0.529–0.84) | 0.079 | 0.744 | 0.738 | 0.197 |
| CD61+-EVs | 0.657 (0.51–0.804) | 0.045 | 0.641 | 0.739 | 0.0992 |
| CD63+-EVs × CA19-9 | 0.906 (0.802–1) | 0.264 | 0.923 | 0.87 | 0.0330 |
| Late-stage (III–IV) | |||||
| CA19-9 | 0.883 (0.773–0.993) | 36 | 0.949 | 0.75 | |
| CD63+-EVs | 0.83 (0.689–0.972) | 0.018 | 0.846 | 0.812 | 0.517 |
| CD41+-EVs | 0.668 (0.495–0.842) | 0.081 | 0.744 | 0.625 | 0.00769 |
| CD61+-EVs | 0.644 (0.468–0.82) | 0.048 | 0.667 | 0.688 | 0.00236 |
| CD63+-EVs × CA19-9 | 0.899 (0.773–1) | 0.136 | 0.872 | 0.875 | 0.809 |
ROC: Receiver operating characteristic, AUC: area under curve, CI: confidence interval
ap-value in DeLong's test